Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.

Tiffany FitzpatrickJames Dayre McNallyTherese A StukelJeffrey C KwongAndrew S WiltonDavid FismanAstrid Guttmann

Published in: Archives of disease in childhood (2020)

Incidence of severe RSV-related illness declined over the study period. While we cannot attribute causality, the timing and magnitude of these declines suggest impact of palivizumab in reducing RSV burden and diminishing social inequities among palivizumab-eligible infants.

Keyphrases

respiratory syncytial virus
randomized controlled trial
healthcare
systematic review
mental health
early onset
emergency department
respiratory tract
drug induced
adverse drug